<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678481</url>
  </required_header>
  <id_info>
    <org_study_id>Pro-Cure PCa 2014</org_study_id>
    <nct_id>NCT02678481</nct_id>
  </id_info>
  <brief_title>MR-targeted vs. Random TRUS-guided Prostate Biopsy</brief_title>
  <acronym>Pro-Cure2014</acronym>
  <official_title>MR-targeted vs. Random TRUS-guided Prostate Biopsy in Patients With High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione del Piemonte per l'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione del Piemonte per l'Oncologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare prostate cancer (PCa) detection rate of magnetic resonance (MR)-targeted biopsy
      and transrectal ultrasound (TRUS)-guided biopsy in patients with high PSA values and at least
      one previous negative prostate biopsy. Subjects will be submitted to a multiparametric MR
      scan of the prostate and subsequently patients with a suspicious MR for PCa presence will be
      randomized (1:1) into the two study arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In men with previously negative prostate biopsy and persistent elevated PSA value, it is
      unclear which biopsy strategy offers the highest detection rate for significant PCa. The
      hypothesis of this study is that MR-targeted biopsy improves the detection rates of
      significant prostate cancers compared with systematic TRUS-guided prostate biopsy.

      Men with at least one previously negative TRUS-guided biopsy and persistently elevated PSA
      values (&gt; 4 ng/ml) will be submitted to a multiparametric MR imaging examination of the
      prostate. Subsequently, participants with suspected regions at MR imaging will be randomized
      (1:1) into the two study arms. In study arm A patients will be submitted to MR-targeted
      in-bore prostate biopsy based on the multiparametric MR imaging findings. In study arm B
      patients will be submitted to systematic TRUS-guided prostate biopsy with saturation scheme.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate cancer detection rate</measure>
    <time_frame>within the 3 months after MR imaging</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MR-targeted biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MR imaging two targeted biopsy cores will be taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRUS-guided biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of arm B receive a saturation TRUS-guided prostate biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR-guided in-bore prostate biopsy</intervention_name>
    <description>2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging</description>
    <arm_group_label>MR-targeted biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TRUS-guided prostate biopsy</intervention_name>
    <description>24-28 systematic biopsy core (saturation scheme)</description>
    <arm_group_label>TRUS-guided biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men aged 50-80

          -  at least one negative TRUS-guided prostate biopsy

          -  PSA &gt; 4 ng/ml

          -  at least one suspected region detected at multiparametric MR imaging

          -  signed informed consent

        Exclusion Criteria:

          -  known prostate cancer diagnosis

          -  contraindication against MR imaging or uncooperative patients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniele Regge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione del Piemonte per l'Oncologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniele Regge, MD</last_name>
    <phone>+39 011 9933 367</phone>
    <email>daniele.regge@ircc.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute</name>
      <address>
        <city>Candiolo</city>
        <state>Turin</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Russo, MD</last_name>
      <phone>+39 011 9933 367</phone>
      <email>filippo.russo@ircc.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiparametric magnetic resonance imaging</keyword>
  <keyword>MR-targeted prostate biopsy</keyword>
  <keyword>saturation TRUS-guided prostate biopsy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

